In last trading session, Lineage Cell Therapeutics Inc (AMEX:LCTX) saw 1.68 million shares changing hands with its beta currently measuring 1.25. Company’s recent per share price level of $0.52 trading at -$0.01 or -2.38% at ring of the bell on the day assigns it a market valuation of $114.66M. That closing price of LCTX’s stock is at a discount of -209.62% from its 52-week high price of $1.61 and is indicating a premium of 7.69% from its 52-week low price of $0.48. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.5 million shares which gives us an average trading volume of 1.89 million if we extend that period to 3-months.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
Upright in the red during last session for losing -2.38%, in the last five days LCTX remained trading in the green while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $0.52 price level, adding 9.99% to its value on the day. Lineage Cell Therapeutics Inc’s shares saw a change of 3.52% in year-to-date performance and have moved 0.19% in past 5-day. Lineage Cell Therapeutics Inc (AMEX:LCTX) showed a performance of -20.70% in past 30-days. Number of shares sold short was 22.03 million shares which calculate 18.69 days to cover the short interests.
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
This year revenue growth is estimated to fall -14.13% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.01M for the same. And 6 analysts are in estimates of company making revenue of 2.01M in the next quarter. Company posted 1.44M and 1.41M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -2.93% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -20.37% while estimates for its earnings growth in next 5 years are of -0.74%.
Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders
Insiders are in possession of 0.55% of company’s total shares while institution are holding 53.91 percent of that, with stock having share float percentage of 54.20%. Investors also watch the number of corporate investors in a company very closely, which is 53.91% institutions for Lineage Cell Therapeutics Inc that are currently holding shares of the company. BROADWOOD CAPITAL INC is the top institutional holder at LCTX for having 41.67 million shares of worth $41.55 million. And as of 2024-06-30, it was holding 22.0675 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 9.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.2264 of outstanding shares, having a total worth of $9.53 million.
